相似文献
1
Editorial: Anti-infective 2020: HIV-From pathogenesis to treatment.
Curr Opin Pharmacol. 2020 Oct;54:x-xii. doi: 10.1016/j.coph.2020.12.001.
2
Perspectives in HIV pathogenesis, treatment, and prevention.
Biomed Pharmacother. 2003 Jan;57(1):1-3. doi: 10.1016/s0753-3322(02)00002-1.
3
Genetic control of HIV disease.
Trends Microbiol. 2003 Aug;11(8):392-7. doi: 10.1016/s0966-842x(03)00177-x.
4
Antiretroviral therapy for advanced naïve HIV-infected patients: current status and comparison of two different management strategies.
J Acquir Immune Defic Syndr. 2007 Sep;46 Suppl 1:S1-2. doi: 10.1097/01.qai.0000286594.11191.91.
5
Long-term suppression of HIV replication in patients with sustained benefit on zidovudine monotherapy.
AIDS. 1998 May 28;12(8):964-6.
6
Changes in plasma HIV-RNA and CD4 lymphocyte counts in patients receiving highly active antiretroviral therapy.
AIDS. 1999 Aug 20;13(12):1594-5. doi: 10.1097/00002030-199908200-00029.
7
25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines.
Clin Exp Immunol. 2008 Oct;154(1):6-14. doi: 10.1111/j.1365-2249.2008.03750.x. Epub 2008 Aug 29.
8
Editorial comment: treatment of acute HIV infection--uncertainties about best practice.
AIDS Read. 2005 May;15(5):250-1.
9
[HIV genetic diversity and its consequences].
Pathol Biol (Paris). 2009 Mar;57(2):142-8. doi: 10.1016/j.patbio.2008.04.004. Epub 2008 Jun 3.
10
Retrovirus meeting. Gut assumes sinister new role in HIV pathogenesis.
Science. 2005 Mar 4;307(5714):1395. doi: 10.1126/science.307.5714.1395.
引用本文的文献
1
[Immunological Causes of Oral Manifestations of HIV Infection: A Literature Review].
Rev Cient Odontol (Lima). 2025 May 16;13(2):e242. doi: 10.21142/2523-2754-1302-2025-242. eCollection 2025 Apr-Jun.
2
Introducing the NUATEI Consortium: A Mexican Research Program for the Identification of Natural and Synthetic Antimicrobial Compounds for Prevalent Infectious Diseases.
Pharmaceuticals (Basel). 2024 Jul 18;17(7):957. doi: 10.3390/ph17070957.
本文引用的文献
1
Therapeutic avenues for restoring the gut microbiome in HIV infection.
Curr Opin Pharmacol. 2020 Oct;54:188-201. doi: 10.1016/j.coph.2020.09.010. Epub 2020 Nov 30.
2
Non-nucleoside reverse transcriptase inhibitors (NNRTIs): a brief overview of clinically approved drugs and combination regimens.
Curr Opin Pharmacol. 2020 Oct;54:179-187. doi: 10.1016/j.coph.2020.10.009. Epub 2020 Nov 14.
3
Embracing diversity: how can broadly neutralizing antibodies effectively target a diverse HIV-1 reservoir?
Curr Opin Pharmacol. 2020 Oct;54:173-178. doi: 10.1016/j.coph.2020.10.004. Epub 2020 Nov 12.
4
Recent discoveries in HIV-1 reverse transcriptase inhibitors.
Curr Opin Pharmacol. 2020 Oct;54:166-172. doi: 10.1016/j.coph.2020.09.017. Epub 2020 Nov 8.
5
Design strategies for long-acting anti-HIV pharmaceuticals.
Curr Opin Pharmacol. 2020 Oct;54:158-165. doi: 10.1016/j.coph.2020.10.005. Epub 2020 Nov 8.
6
RNAi therapeutics: an antiviral strategy for human infections.
Curr Opin Pharmacol. 2020 Oct;54:121-129. doi: 10.1016/j.coph.2020.09.011. Epub 2020 Nov 7.
7
Pharmacologic approaches to HIV-associated neurocognitive disorders.
Curr Opin Pharmacol. 2020 Oct;54:102-108. doi: 10.1016/j.coph.2020.09.003. Epub 2020 Oct 10.
8
Barriers and strategies to achieve a cure for HIV.
Lancet HIV. 2018 Jun;5(6):e317-e328. doi: 10.1016/S2352-3018(18)30039-0.
9
Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.
Nat Med. 2018 Jul;24(7):923-926. doi: 10.1038/s41591-018-0026-6. Epub 2018 Jun 11.
10
CD8+ T cells with high TGF‑β1 expression cause lymph node fibrosis following HIV infection.
Mol Med Rep. 2018 Jul;18(1):77-86. doi: 10.3892/mmr.2018.8964. Epub 2018 May 3.
Zotero 插件